| 001 | 305584 | ||
| 005 | 20251102023529.0 | ||
| 024 | 7 | _ | |a 10.1016/S1470-2045(25)00426-7 |2 doi |
| 024 | 7 | _ | |a pmid:41167226 |2 pmid |
| 024 | 7 | _ | |a 1470-2045 |2 ISSN |
| 024 | 7 | _ | |a 1474-5488 |2 ISSN |
| 024 | 7 | _ | |a altmetric:182962476 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2025-02243 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Sanz, Jaime |b 0 |
| 245 | _ | _ | |a Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee. |
| 260 | _ | _ | |a London |c 2025 |b The Lancet Publ. Group |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1761918006_171915 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Measurable residual disease (MRD) is a key predictor of relapse, the primary cause of treatment failure after allogeneic haematopoietic cell transplantation (allo-HCT) in acute myeloid leukaemia. This Policy Review, based on guidance from the European Society for Blood and Marrow Transplantation, provides practical recommendations for incorporating MRD assessment into clinical decision making during the transplantation process, the application of which remains challenging in acute myeloid leukaemia due to technical limitations and the limited availability of standardised, evidence-based approaches. Available methods include reverse transcription quantitative PCR, digital droplet PCR, next-generation sequencing, and multiparametric flow cytometry-chimerism-based approaches are under investigation. This Policy Review highlights the importance of MRD monitoring to enable timely, risk-adapted interventions that encompass both pre-transplantation and post-transplantation periods and can include tailoring conditioning intensity, donor selection, immunosuppression management, donor lymphocyte infusions, and pharmacological therapies such as FLT3 or IDH inhibitors, hypomethylating agents, venetoclax, or menin inhibitors. These recommendations aim to harmonise MRD-driven clinical practice and improve patient outcomes, while identifying key areas for future research. |
| 536 | _ | _ | |a 899 - ohne Topic (POF4-899) |0 G:(DE-HGF)POF4-899 |c POF4-899 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Neoplasm, Residual |2 MeSH |
| 650 | _ | 2 | |a Hematopoietic Stem Cell Transplantation: standards |2 MeSH |
| 650 | _ | 2 | |a Hematopoietic Stem Cell Transplantation: adverse effects |2 MeSH |
| 650 | _ | 2 | |a Leukemia, Myeloid, Acute: therapy |2 MeSH |
| 650 | _ | 2 | |a Leukemia, Myeloid, Acute: pathology |2 MeSH |
| 650 | _ | 2 | |a Leukemia, Myeloid, Acute: genetics |2 MeSH |
| 650 | _ | 2 | |a Transplantation, Homologous |2 MeSH |
| 650 | _ | 2 | |a Europe |2 MeSH |
| 650 | _ | 2 | |a Transplantation Conditioning |2 MeSH |
| 650 | _ | 2 | |a Clinical Decision-Making |2 MeSH |
| 700 | 1 | _ | |a Bug, Gesine |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Ciceri, Fabio |b 2 |
| 700 | 1 | _ | |a Craddock, Charles |b 3 |
| 700 | 1 | _ | |a Dillon, Richard |b 4 |
| 700 | 1 | _ | |a Esteve, Jordi |b 5 |
| 700 | 1 | _ | |a Porta, Matteo Giovanni Della |b 6 |
| 700 | 1 | _ | |a Heuser, Michael |b 7 |
| 700 | 1 | _ | |a de Leeuw, David C |b 8 |
| 700 | 1 | _ | |a Nagler, Arnon |b 9 |
| 700 | 1 | _ | |a Onida, Francesco |b 10 |
| 700 | 1 | _ | |a Roboz, Gail J |b 11 |
| 700 | 1 | _ | |a Ruggeri, Annalisa |b 12 |
| 700 | 1 | _ | |a Sánchez-Ortega, Isabel |b 13 |
| 700 | 1 | _ | |a Srour, Micha |b 14 |
| 700 | 1 | _ | |a Yakoub-Agha, Ibrahim |b 15 |
| 700 | 1 | _ | |a Buccisano, Francesco |b 16 |
| 773 | _ | _ | |a 10.1016/S1470-2045(25)00426-7 |g Vol. 26, no. 11, p. e586 - e596 |0 PERI:(DE-600)2035574-9 |n 11 |p e586 - e596 |t The lancet / Oncology |v 26 |y 2025 |x 1470-2045 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:305584 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-HGF)0 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF4-890 |0 G:(DE-HGF)POF4-899 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-800 |4 G:(DE-HGF)POF |v ohne Topic |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-17 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-17 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b LANCET ONCOL : 2022 |d 2024-12-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-17 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-17 |
| 915 | _ | _ | |a IF >= 50 |0 StatID:(DE-HGF)9950 |2 StatID |b LANCET ONCOL : 2022 |d 2024-12-17 |
| 920 | 1 | _ | |0 I:(DE-He78)FM01-20160331 |k FM01 |l DKTK Koordinierungsstelle Frankfurt |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)FM01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::